<?xml version="1.0" encoding="UTF-8"?>
<ref id="b0320">
 <label>64</label>
 <element-citation publication-type="journal" id="h0320">
  <person-group person-group-type="author">
   <name>
    <surname>Borucki</surname>
    <given-names>M.J.</given-names>
   </name>
   <name>
    <surname>Spritzler</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Asmuth</surname>
    <given-names>D.M.</given-names>
   </name>
   <name>
    <surname>Gnann</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Hirsch</surname>
    <given-names>M.S.</given-names>
   </name>
   <name>
    <surname>Nokta</surname>
    <given-names>M.</given-names>
   </name>
  </person-group>
  <article-title>A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis</article-title>
  <source>Antiviral Res.</source>
  <volume>64</volume>
  <issue>2</issue>
  <year>2004</year>
  <fpage>103</fpage>
  <lpage>111</lpage>
  <pub-id pub-id-type="pmid">15498605</pub-id>
 </element-citation>
</ref>
